D2R activation has also been shown to be relevant to dopamine uptake by vesicular monoamine transporter-2 (VMAT-2) [29], suggesting that its pharmacological modulation may be a non-canonical therapeutic target in the treatment of schizophrenia [30]. This evidence concerns the gene SLC18A2 and schizophrenia.